• DOI:10.1186/2193-1801-3-5
Corpus ID: 12995745

Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL

@article{Hohloch2014SignificantDE,
  title={Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL},
  author={K. Hohloch and C. Zwick and M. Ziepert and D. Hasenclever and U. Kaiser and A. Engert and H. Hoeffkes and F. Kroschinsky and R. Mesters and Andreas Feller and M. Loeffler and L. Tr{\"u}mper and M. Pfreundschuh},
  journal={SpringerPlus},
  year={2014},
  volume={3}
}

K. Hohloch, C. Zwick, +10 authors M. Pfreundschuh

Published 2014

Medicine

SpringerPlus

BackgroundDose escalation and modification of CHOP has improved the prognosis of patients with aggressive lymphoma; even in the rituximab era, dose escalation for high-risk patients is exploited and frequently limited by drug toxicity. Idarubicin (Id) is a 4-demethoxy anthracycline analogue of daunorubicin with activity against lymphoma and has been reported to cause less cardiotoxicity than other anthracylines. The aim of this study was to replace doxorubicine with idarubicin in the CHOEP… CONTINUE READING

View on Springer

springerplus.springeropen.com

Save to Library

Create Alert

Cite

Launch Research Feed